drugset / Trial / NCT01260467

Memantine for Recurrent Glioblastoma

NCT01260467

Phase 2 Terminated 4 enrolled University of Rochester
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth of brain tumors. It has previously been studied for other types of conditions, such as Alzheimer's disease, but it has not yet been evaluated in the treatment of brain tumors. The investigators will also be determining how common it is for patients with brain tumors to have side effects to memantine. Memantine will be taken by mouth twice a day.

Timeline

Start
2010-11
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Memantine Unknown 10 mg Oral

Indications